PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
34373541-1	2021	We have recently described Pz-1, a benzimidazole-based type-2 RET and VEGFR2 inhibitor.	benzimidazole	35-48	kinase insert domain receptor	Homo sapiens	70-76	
21724404-0	2011	Discovery of benzimidazole derivatives as novel multi-target EGFR, VEGFR-2 and PDGFR kinase inhibitors.	benzimidazole	13-26	kinase insert domain receptor	Homo sapiens	67-74	
21724404-2	2011	In this work, we used two virtual screening methods, support vector machines (SVM) and molecular docking, to identify a novel series of benzimidazole derivatives, 2-aryl benzimidazole compounds, as multi-target EGFR, VEGFR-2 and PDGFR inhibitors.	benzimidazole	136-149	kinase insert domain receptor	Homo sapiens	217-224	
21724404-7	2011	Our study discovered a novel series of benzimidazole derivatives as multi-target EGFR, VEGFR-2 and PDGFR kinases inhibitors.	benzimidazole	39-52	kinase insert domain receptor	Homo sapiens	87-94	
17676829-3	2007	The SAR results were also supported by the X-ray crystallographic elucidation of the role of the N1 nitrogen and the urea moiety when the benzimidazole-urea compounds were bound to the VEGFR-2 enzyme.	benzimidazole	138-151	kinase insert domain receptor	Homo sapiens	185-192	
32053964-0	2020	Targeting Receptor Tyrosine Kinase VEGFR-2 in Hepatocellular Cancer: Rational Design, Synthesis and Biological Evaluation of 1,2-Disubstituted Benzimidazoles.	benzimidazole	125-157	kinase insert domain receptor	Homo sapiens	35-42	
32053964-3	2020	Our second objective was to further optimize the structures of the benzimidazole derivatives through elongation of the side chains at their one-position for the design of more potent type II-like VEGFR-2 inhibitors.	benzimidazole	67-80	kinase insert domain receptor	Homo sapiens	196-203	
32053964-7	2020	Molecular docking studies of the synthesized 1,2-disubstituted benzimidazoles in the VEGFR-2 active site displayed their ability to accomplish the essential hydrogen bonding and hydrophobic interactions for optimum inhibitory activity.	benzimidazole	63-77	kinase insert domain receptor	Homo sapiens	85-92	
31252306-0	2019	Design, synthesis and in vitro evaluation of 6-amide-2-aryl benzoxazole/benzimidazole derivatives against tumor cells by inhibiting VEGFR-2 kinase.	benzimidazole	72-85	kinase insert domain receptor	Homo sapiens	132-139	
31252306-2	2019	A library of thirty-seven 6-amide-2-aryl benzoxazole/benzimidazole derivatives has been designed and synthesized based on the highly conserved active site of VEGFR-2.	benzimidazole	53-66	kinase insert domain receptor	Homo sapiens	158-165	
31131561-7	2019	In general, these results indicate that these 6-arylurea-2-arylbenzoxazole/benzimidazole derivatives are promising inhibitors of VEGFR-2 kinase for potential development into anti-angiogenesis drugs.	benzimidazole	75-88	kinase insert domain receptor	Homo sapiens	129-136	
28638907-0	2017	Ruthenium(ii) p-cymene complexes of a benzimidazole-based ligand capable of VEGFR2 inhibition: hydrolysis, reactivity and cytotoxicity studies.	benzimidazole	38-51	kinase insert domain receptor	Homo sapiens	76-82	
28638907-3	2017	In our work, we have generated a bispyrazole-containing benzimidazole ligand with potency against vascular endothelial growth factor receptor 2 (VEGFR2), which is known to have roles in vasculogenesis/angiogenesis.	benzimidazole	56-69	kinase insert domain receptor	Homo sapiens	98-143	
28638907-3	2017	In our work, we have generated a bispyrazole-containing benzimidazole ligand with potency against vascular endothelial growth factor receptor 2 (VEGFR2), which is known to have roles in vasculogenesis/angiogenesis.	benzimidazole	56-69	kinase insert domain receptor	Homo sapiens	145-151	
25082515-0	2014	Discovery of quinazolin-4-amines bearing benzimidazole fragments as dual inhibitors of c-Met and VEGFR-2.	benzimidazole	41-54	kinase insert domain receptor	Homo sapiens	97-104	
25082515-3	2014	Among these compounds bearing quinazoline and benzimidazole fragments, compound 7j exhibited the most potent inhibitory activity against c-Met and VEGFR-2 with IC50 of 0.05muM and 0.02muM, respectively.	benzimidazole	46-59	kinase insert domain receptor	Homo sapiens	147-154	
32689708-0	2015	Corrigendum to "Discovery of quinazolin-4-amines bearing benzimidazole fragments as dual inhibitors of c-Met and VEGFR-2" [Bioorg.	benzimidazole	57-70	kinase insert domain receptor	Homo sapiens	113-120